Figure 3
Proportion of patients with and without sleep improvement achieving DLQI endpoints at Week 16. AD: atopic dermatitis; DLQI: Dermatology Life Quality Index. **p<0.01, ***p<0.001. Sleep improvement is defined as a ≥1.5-point decrease in Atopic Dermatitis Sleep Scale Item 2 score at Week 16. Analysis included patients with baseline DLQI scores ≥4, or ≥1, depending on the outcome assessed. Logistic regression models were used with terms for baseline disease severity (vIGA-AD), baseline value, region, treatment group, itch/sleep improvement (yes or no), and the interaction of treatment and itch/sleep response; non-responder imputation was applied for missing data.